Canada has decided to cancel a coronavirus vaccine development agreement with the Chinese pharmaceutical company CanSino due to delay in the shipping of drugs. The Council said it has turned to its North American partners for collaboration and will go ahead in its COVID-19 vaccine development programme. CanSino, earlier this week, had refuted that ties had been cut, however, the government-funded body has now confirmed that clinical trials of vaccine candidate Ad5-nCoV would not go ahead in Canada. According to the South China Morning Post, Ad5-nCoV, developed by China military scientists is among the leaders to produce a Covid-19 vaccine. The National Research Council had signed an agreement with CanSino to conduct phase 1 trials in May.

Source: dna August 30, 2020 00:11 UTC